Dose-reduced (24 Gy) involved-site radiotherapy combined with rituximab in early-stage non-gastric mucosa-associated lymphoid tissue lymphoma: a prospective phase II trial.
LeukemiaJul 16, 2026 (epub)
Hailing Liu, Yuexin Cheng, Shu Liu et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective phase II trial evaluated the efficacy of 24 Gy involved-site radiotherapy combined with rituximab in 60 patients with early-stage non-gastric mucosa-associated lymphoid tissue lymphoma. The treatment achieved a complete response rate of 100%, with a median follow-up of 30.2 months showing only one distant recurrence, resulting in an estimated 5-year distant recurrence rate of 1.9%.
Key findings
- Complete response rate of 100% in the per-protocol efficacy-evaluable cohort (n = 55).
- Estimated 5-year distant recurrence rate of 1.9% at a median follow-up of 30.2 months.
- 2- and 4-year progression-free survival rates were 98.0% and 92.9%, respectively, in the full analysis set.
- 23.3% of patients experienced infections, including one grade 4 respiratory infection.
Why it matters
The study highlights a promising treatment approach for early-stage non-gastric MALT lymphoma, potentially reducing distant relapses and improving long-term survival outcomes. Clinicians may consider this regimen for enhanced disease control.